Hypertrophic Cardiomyopathy (HCM) Treatment Market

The global Hypertrophic Cardiomyopathy (HCM) Treatment market size was USD 1.28 billion in 2023, and is calculated at USD 1.99 Billion in 2024. The market is projected to reach USD 31.11 Billion by 2034, and register a revenue 4.1% over the forecast period (2025-2034).

Premium Insights:

Global Hypertrophic Cardiomyopathy (HCM) Treatment market revenue growth is driven by increasing number of individuals seeking medical assistance related to heart and chest pain, shortness of breath, and heart palpitations, and increasing numbers being diagnosed with genetic defects based on medical history, family history, and gene mutations more recently.

Trends such as preventive healthcare and preventive medicine as well as technological advancements and advances in medical fields and research initiatives have also been serving to identify, diagnose, and establish causes of various diseases, genetic conditions, and related symptoms and outcomes. The number of individuals seeking opinion and diagnosis from professionals or medical and experts regarding potential genetic predispositions and family and genetic history has been increasing significantly and this is also a major factor resulting in the number of diagnosed cases of HCM rising in parallel. Advancements in medical technology and diagnostic tools continue to enable detection of HCM cases, and the positive outcomes have been resulting in more individuals opting for testing, diagnosis, as well as the various treatment options. Gene mutation is a major focus area currently, and rising prevalence of risk factors such as hypertension, early onset of aging, rapidly aging populations, and inclining obesity worldwide are further stimulating progress and initiatives in various fields of medicine and healthcare.

HCM is often inherited in an autosomal dominant pattern, but can also occur when a gene mutates, even if no family history exists. Other known factors that contribute to HCM are uncontrolled high blood pressure, heightened sympathetic stimulation, abnormally thickened coronary arteries, and abnormal microcirculation. More recent research indicates that around 60% of HCM patients have a known gene mutation. HCM is a heart disorder that stems from mutations in the gene responsible for producing sarcomere proteins, which are key to heart contraction. In HCM, the left ventricular wall thickens, leading to issues such as obstruction of blood flow from the left ventricle, along with diastolic symptoms like chest pain, shortness of breath, and heart palpitations, although some individuals may experience no symptoms at all.

Treatment for HCM often involves medications such as beta-blockers and calcium channel blockers to help alleviate symptoms and enhance heart function. Another common approach is alcohol septal ablation, which is a catheter-based procedure involving injection of a small amount of pure alcohol into the thickened part of the septum, causing it to shrink and clear a path for blood flow. Septal myectomy is the option for those needing surgical intervention, and this procedure involves removal of part of the thickened septal wall to further open the outflow tract and relieve obstruction.

Personalized medicine and approaches have also been gaining steady traction, and this is driving demand for innovative medications, drugs, therapeutics, and targeted treatments tailored to individual genetic profiles. Supporting Research and Development (R&D) initiatives in the pharmaceutical sector and integration of genetic testing into routine healthcare practices is another trend aiding in early identification and treatment initiation for HCM patients. This trend is more prominent in the US and some countries in Europe with presence of modernized healthcare infrastructure and early adoption of new and novel treatments and approaches in the healthcare sector. Pharmaceutical companies active in this market are entering into partnerships with research institutions, and conducting various tests and trials to promoting development of new medications. A steadily evolving reimbursement landscape in healthcare, as well as for HCM therapies, are also factors driving market growth. Companies are also focused on developing new drugs to maintain a competitive edge and drive innovation in drug development to introduce more effective treatment options. Securing approval from the concerned administration and authority is also a key focus area in the market.

Top Hypertrophic Cardiomyopathy (HCM) Treatment Market Drivers and Trends:

• Increased Focus on Early Diagnosis and Preventive Healthcare: Early diagnosis of HCM is on the rise with more individuals actively seeking medical advice due to family history or genetic risk. Rising focus on preventive care encourages earlier intervention, allowing for timely management and better patient outcomes.
• Advances in Diagnostic Technology: Progress in medical technology has made it easier to detect HCM through advanced imaging and diagnostic tools. This increased diagnostic capability leads to higher diagnosis rates and rising awareness in this regard is driving demand for HCM treatments.
• Rising Prevalence of Risk Factors: Factors such as hypertension and aging global population are contributing to a larger patient pool at risk for HCM. Rising prevalence of these factors and increasing focus across the healthcare sector to deploy measures and programs to enable meeting rising patient footfalls with age-related conditions and diseases, genetic mutations, heart conditions, and increasing pool of patients seeking preventive treatment and management solutions are key factors supporting growth of the market.
• Steady Traction of Personalized Medicine and Targeted Therapies: The trend toward treatments tailored to individual genetic profiles is driving demand for innovative medications in HCM care. Pharmaceutical companies are increasing R&D efforts to develop targeted therapies that address unique genetic underpinnings of HCM. This is also expected to support growth of the market.
• Integration of Genetic Testing in Healthcare: Genetic testing is increasingly becoming part of routine healthcare, particularly in the US and some countries in Europe. This integration supports early detection of HCM and proactive treatment, making HCM management more accessible and effective.
• Collaborative R&D Efforts: Partnerships between pharmaceutical companies and research institutions are encouraging and driving creation of novel HCM treatments. These collaborations are also adding to the intensity of competition in the market, by expanding the range of available treatment options.
• Enhanced Insurance and Reimbursement Policies: Improving reimbursement and insurance coverage for HCM therapies are reducing financial barriers for patients are key factors encouraging more individuals to seek treatment. This barrier has been a major restraint or challenge to individuals seeking medical interventions in the past, and emergence of more favorable policies are expected to have a positive impact and support market growth.

Hypertrophic Cardiomyopathy (HCM) Treatment Market Restraining Factor Insights

• High Cost of Treatment and Limited Accessibility: HCM treatments, particularly novel therapies like myosin inhibitors and advanced surgical procedures, are often expensive and may not be covered fully by insurance, thereby limiting access for many patients. The costs of lifelong drug therapy, such as ongoing prescriptions for beta blockers or newly approved myosin inhibitors, can add up significantly, creating financial strain for patients. Moreover, advanced diagnostics like cardiac MRI and genetic testing are costly and may not be readily available in rural or low-income areas, leading to delayed or limited treatment uptake. These financial and accessibility issues can reduce overall market demand, especially in emerging economies.
• Limited Research and Development Progress: Developing targeted treatments for HCM is challenging due to the genetic and clinical variability of the disease, which complicates drug development and clinical trial design. The need for specific biomarkers and reliable clinical endpoints further adds complexities to R&D efforts, making it difficult to produce highly effective, safe, and broadly applicable treatments. Also, some promising drugs in clinical trials face setbacks or fail to meet efficacy and safety standards, leading to high attrition rates in the HCM drug pipeline. This limited R&D progress delays the introduction of innovative therapies and can negatively impact market revenue as fewer new treatments reach the market.
• Potential Side Effects and Long-Term Safety Concerns: HCM treatments, particularly pharmaceutical options, carry risks of adverse effects, and patients can experience fatigue, dizziness, and gastrointestinal issues, which can discourage patient compliance and long-term use. For instance, beta blockers and calcium channel blockers, while effective, often produce side effects that impact patients' daily lives. In addition, the long-term safety of new drugs like myosin inhibitors remains under scrutiny, as real-world data is still being collected. These safety concerns and side effects can lead to hesitation among patients and providers, potentially reducing the market penetration of treatments. Trends in personalized medicine and non-invasive approaches may further shift preference away from pharmaceuticals if long-term safety risks become more apparent.

Hypertrophic Cardiomyopathy (HCM) Treatment Market Opportunities

• Investment in Precision Medicine and Genetic Testing: Companies can expand product portfolios by investing in precision medicine, including genetic testing and targeted therapies. Given the genetic basis of HCM, advanced testing can provide early and accurate diagnosis, enabling tailored treatments that improve patient outcomes. Collaborating with diagnostic firms or developing in-house genetic testing solutions could create a new revenue stream, as demand rises for personalized HCM management. Moreover, precision medicine aligns with broader shift towards individualized treatment in healthcare, offering pharmaceutical firms a competitive advantage and encouraging adoption by healthcare providers.
• Expansion of Geographic Market Reach and Access Initiatives: Major companies can explore growth avenues by expanding into emerging markets, where HCM awareness and infrastructure for diagnosis are improving. This can be achieved through partnerships with local healthcare providers, pricing strategies adapted for diverse economic settings, and public health initiatives aimed at educating populations and healthcare professionals about HCM. By encouraging early diagnosis and treatment access in regions like Asia Pacific and Latin America, companies can tap into underserved patient populations, increase market share, and achieve long-term growth. Also, offering tiered pricing for low- and middle-income countries can promote adoption and generate revenue.
• Strategic Partnerships, Acquisitions, and R&D Investment in Myosin Inhibitors: Leading companies can enhance their market position and product offerings by acquiring smaller biotech firms with promising HCM drugs, particularly myosin inhibitors. Partnerships with academic institutions for research and clinical trials can also support pipeline development, ensuring a steady flow of innovative therapies. By focusing on drugs targeting HCM’s molecular drivers, companies can leverage and serve high-value segments, and differentiating themselves in an increasingly competitive market.

Hypertrophic Cardiomyopathy (HCM) Treatment Market Segmentation:

By Treatment Type

• Drug Therapy
• Surgical Procedures
• Non-Surgical Procedures
• Lifestyle and Non-Pharmacological Management

By Drug Class

• Beta Blockers
• Calcium Channel Blockers
• Antiarrhythmic Drugs
• Myosin Inhibitors

By Diagnosis & Monitoring

• Genetic Testing
• Imaging (Echocardiography, MRI)
• Electrocardiogram (ECG)
• Blood Tests

By End User

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Homecare Settings

Segment Insights:

By Treatment Type:

The drug therapy segment is expected to account for largest revenue share among the treatment type segments over the forecast period. Factors expected to continue to drive growth of this segment include increasing demand for targeted pharmacological solutions that manage HCM symptoms with minimal invasiveness. Drugs such as beta blockers, calcium channel blockers, and especially emerging myosin inhibitors (eg., mavacamten), offer specific symptom relief and disease modification, thereby improving quality of life of patients and delaying the need for invasive interventions. The shift towards personalized medicine and continuous advancements in pharmacology is also supporting adoption of drug therapy. In addition, healthcare providers and patients ideally prefer medication over surgeries due to lower costs, shorter recovery times, and less physical strain. Moreover, demand for effective, accessible treatment options is expected to result in drug therapy remaining at the forefront of HCM management as awareness regarding HCM continues to grow and diagnostic rates increase.

By Drug Class:

The myosin inhibitors segment is expected to lead in terms of revenue share among the drug class segments over the forecast period. This can be attributed to the innovative mechanism of action of this drug class, which directly targets the pathophysiology of HCM by reducing hypercontractility in the heart muscle. FDA approval of mavacamten, which is the first drug specifically designed for obstructive HCM, has generated substantial interest in myosin inhibitors, positioning drugs of this class as transformative therapies in this market. Unlike traditional HCM drugs, myosin inhibitors are more effective at treating the root cause rather than merely managing symptoms, resulting in higher efficacy and better patient outcomes. Ongoing clinical trials and strong pipeline activity is expected to position myosin inhibitors as a standard treatment, and as physicians continue to recommend and adopt these targeted therapies, revenue growth in this segment is expected to remain steady over the forecast period.

By Diagnosis & Monitoring:

The imaging segment is expected to dominate others among the diagnosis and monitoring segments over the forecast period. Imaging plays an essential role in the initial detection, evaluation, and ongoing management of HCM. Echocardiography is often the first-line imaging tool for assessing heart structure and function in suspected HCM patients, while MRI provides detailed insights into myocardial fibrosis and ventricular morphology. Both techniques are critical for diagnosing HCM accurately, stratifying patients by risk, and planning personalized treatment strategies. Advances in imaging technology, such as 3D echocardiography and cardiac MRI, are enhancing diagnostic precision and offering non-invasive ways to monitor disease progression, making them indispensable in clinical practice. With increased HCM awareness and improved access to imaging facilities globally, the adoption of advanced imaging techniques is likely to grow, thereby supporting revenue growth of this segment.

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

By End User:

The hospitals segment is expected to account for largest revenue share among the end-user segments over the forecast period. Hospitals are considered as primary care providers for initial HCM diagnosis, treatment, and management. Hospitals typically offer a full range of services needed for HCM patients, including specialized cardiac care units, advanced diagnostic imaging, genetic testing, and surgical capabilities. Also, the complexity of HCM cases often requires multidisciplinary care involving cardiologists, surgeons, and genetic counselors — roles that hospitals are uniquely positioned to integrate. Hospitals also serve as sites for clinical trials and advanced HCM research, and global rise in healthcare infrastructure spending and development in emerging economies and expanding cardiovascular services are factors expected to further drive revenue growth of this segment.

Regions and Countries

North America

• United States
• Canada
• Mexico

Europe

• Germany
• United Kingdom
• France
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India

Rest of Asia Pacific

• Latin America
• Brazil
• Argentina

Rest of Latin America

• Middle East & Africa
• Saudi Arabia
• South Africa
• United Arab Emirates
• Israel
• Rest of MEA

Hypertrophic Cardiomyopathy (HCM) Treatment Market Regional Landscape:

Among the regional markets in 2023, North America led in terms of revenue share, driven largely by the US. This dominance is supported by high awareness regarding HCM, robust healthcare infrastructure, and a favorable regulatory environment for advanced therapies. Companies such as Bristol Myers Squibb and Pfizer are based in the US, and are focusing extensively on HCM drug development and offering treatment options for both obstructive and non-obstructive HCM. Canada also contributes, though to a lesser extent, due to its smaller population but strong healthcare standards.

Europe market position is supported by revenue contributions from Germany, the UK, and France, where government support for cardiovascular health programs has strengthened HCM diagnosis and treatment rates. Companies like Novartis and Sanofi play a vital role in the market scenario, often tailoring products to meet the specific regulatory requirements and healthcare needs of European countries. Increasing emphasis on early diagnosis through genetic testing in these countries is also expected to further drive demand.

In Asia Pacific, Japan, China, and India are key markets, with Japan leading in early adoption of advanced diagnostic and treatment technologies. Takeda (Japan) and Sun Pharmaceuticals (India) are important regional players, helping to meet growing HCM awareness and needs in Asia. Government healthcare programs and improving infrastructure, especially in China and India, are boosting market potential in the region.

Hypertrophic Cardiomyopathy (HCM) Treatment Market Competitive Landscape:

Company List:

• Bristol Myers Squibb (BMS)
• Cytokinetics, Inc.
• Novartis AG
• Sanofi
• Pfizer Inc.
• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• Amgen Inc.
• Alexion Pharmaceuticals, Inc. (AstraZeneca)
• Takeda Pharmaceutical Company Limited

Competitive Landscape:

The competitive landscape in the global Hypertrophic Cardiomyopathy (HCM) Treatment market is characterized by a growing number of pharmaceutical companies, biotech firms, and diagnostic providers striving to capitalize on the increasing demand for effective HCM treatments. The market is currently dominated by key players such as Bristol Myers Squibb (BMS), Cytokinetics, Novartis, Sanofi, and Pfizer, which are focusing on developing and commercializing innovative therapies, particularly targeted drugs like mavacamten (BMS) and aficamten (Cytokinetics), to address the underlying mechanisms of HCM. These companies are also engaged in development and provision of advancing diagnostic and monitoring tools, with a significant emphasis on genetic testing and advanced imaging techniques.

To maintain their positions and expand their consumer base, leading companies are adopting various key strategies. Larger companies are increasingly acquiring smaller biotech firms with promising HCM pipelines. Partnerships with academic institutions and research organizations also enable collaboration on clinical trials and access to innovative therapies. Also, companies are expanding their presence in emerging markets as the HCM treatment market grows and gains traction. Tailoring products to meet local regulatory requirements and addressing regional healthcare challenges are also approaches to increase market penetration. Moreover, leading companies are investing substantially in the development of personalized treatments, utilizing genetic testing to better tailor therapies to individual patients. This trend is gaining traction as it enhances treatment efficacy and patient outcomes.​

Recent Developments

• August 15, 2024: Bristol Myers Squibb Canada (BMS) achieved a significant milestone for patients in Quebec and Alberta with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) who qualify for federal government coverage through the Non-Insured Health Benefits (NIHB) Program. CAMZYOS (mavacamten capsules), the first oral cardiac myosin inhibitor approved in Canada for managing oHCM, has now been added to the Régie de l'assurance maladie du Québec (RAMQ) List of Medications, Alberta’s Drug Benefits List, and the NIHB drug plan under Indigenous Services Canada. This inclusion offers coverage to patients who meet specific criteria​. CAMZYOS is uniquely positioned as the only Health Canada-approved myosin inhibitor with reversible action, specifically aimed at treating symptomatic obstructive HCM in adults classified as New York Heart Association (NYHA) Class II-III. By targeting the underlying cause of oHCM, this oral therapy provides a non-invasive treatment option that addresses a key gap in care for individuals with this challenging cardiac condition, offering an alternative to more invasive interventions for eligible patients.
• January 25, 2024: Cytokinetics, Inc. shared new data at CMR 2024 showcasing the effects of aficamten on cardiac structure, function, and fibrosis in patients with hypertrophic cardiomyopathy. The data was derived from the FOREST-HCM study (Follow-up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in HCM), which is an open-label extension trial examining aficamten’s impact in this patient population. The study builds on previous research by assessing aficamten’s potential benefits in enhancing exercise tolerance and alleviating HCM symptoms, as well as its effects on heart structure and functional capacity over an extended period. Cytokinetics’ aficamten development program aims to confirm the drug’s potential in reducing the symptomatic and structural challenges of HCM, with a focus on improving patient quality of life through sustained therapy.
• August 15, 2023: Viz.ai announced securing a De Novo approval by the U.S. Food and Drug Administration (FDA) for its Viz HCM module, which is a hypertrophic cardiomyopathy artificial intelligence detection algorithm. This approval required creation of a new regulatory category for cardiovascular machine learning-based notification software. Deployment of the algorithm is funded by a multi-year agreement with Bristol Myers Squibb announced in March. Viz HCM, which is integrated into the Viz.ai Platform, enables more patients with suspected HCM to be identified earlier using AI and triaged for diagnosis and further evaluation.

Frequently Asked Questions:

Q: What is the global Hypertrophic Cardiomyopathy (HCM) Treatment market size in 2024 and what is the projection for 2034?

A: The global Hypertrophic Cardiomyopathy (HCM) Treatment market size was calculated at USD 1.33 billion in 2024 and expected to reach USD 1.99 billion in 2034

Which regional market accounted for largest revenue share in 2023, and what is the expected trend over the forecast period?

A: North America is expected to account for largest revenue share in the global market over the forecast period.

Q: Which are the major companies are included in the global Hypertrophic Cardiomyopathy (HCM) Treatment market report?

A: Major companies in the market report are Bristol Myers Squibb (BMS), Cytokinetics, Inc., Novartis AG, Sanofi, Pfizer Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd., Amgen Inc., Alexion Pharmaceuticals, Inc. (AstraZeneca), Takeda Pharmaceutical Company Limited.

Q: What is the projected revenue CAGR of the global Hypertrophic Cardiomyopathy (HCM) Treatment market over the forecast period?

A: The global Hypertrophic Cardiomyopathy (HCM) Treatment market is expected to register a CAGR of 4.1% between 2025 and 2034.

Q: What are some key factors driving revenue growth of the Hypertrophic Cardiomyopathy (HCM) Treatment market ?

A: Some key factors driving market revenue growths are increasing number of individuals seeking medical assistance related to heart and chest pain, shortness of breath, heart palpitations, and increasing numbers being diagnosed with genetic defects based on medical history, family history, and gene mutations more recently, as well as growing trends of preventive healthcare and preventive medicine, coupled with technological advancements and advances in medical fields and research initiatives to accurately and effectively identify, diagnose, and establish causes of various diseases, genetic conditions, and related symptoms and outcomes.